Accumulating pieces of evidence report that the KRAS G12C inhibitors such as Sotorasib (AMG 510), ARS-1620, and Adagrasib (MRTX849) are becoming resistant in non-small-cell-lung-cancer (NSCLC) and colorectal-cancer (CRC) patients [44,45]. The gene discussed is KRAS; the disease is colorectal carcinoma.